Reconstitution of Anti‐tumor Effects of Lentinan in Nude Mice: Roles of Delayed‐type Hypersensitivity Reaction Triggered by CD4‐positive T Cell Clone in the Infiltration of Effector Cells into Tumor

Wiley - Tập 85 Số 4 - Trang 409-417 - 1994
Manabu Suzuki1, Michihiro Iwashiro2, Fumihiko Takatsuki3, Kagemasa Kuribayashi2, Junji Hamuro3
1Basic Research Laboratory, Ajinomoto Co. Inc., Kawasaki.
2Institute for Immunology, Faculty of Medicine, Kyoto University, Yoshida‐Konoe‐cho, Sakyo‐ku, Kyoto 606
3Basic Research Laboratories, Central Research Laboratories, Ajinomoto Co. Inc., 1-1 Suzuki-cho, Kawasaki 210

Tóm tắt

Lentinan, an antitumor polysaccharide used clinically in Japan, requires the intact T cell compartment to manifest its antitumor effects. The aim of the current study was to clarify the mechanisms playing crucial roles in the T cell requirement in the expression of antitumor effects of lentinan. Lentinan treatment of BDF1 mice transplanted intradermally with FBL‐3 induced complete tumor regression and a marked increase in survival time. The antitumor action of lentinan was abolished in mice treated simultaneously with antibodies to CD4 and CD8 antigens, whereas antibody to CD4, CD8 or NK1.1 alone was ineffective. The natural killer, cytotoxic T lymphocyte, and helper T cell activities were already augmented in this FBL‐3/BDF1 system and thus further augmentation of these activities by lentinan was not observed. These activities did not correlate with the antitumor activity of lentinan, as was confirmed in lymphocyte subset depletion experiments. On the contrary, the delayed‐type hypersensitivity (DTH) response against tumor‐associated antigens was triggered by lentinan and was abrogated only in mice treated simultaneously with antibodies to CD4 and CD8 antigens. Furthermore, a non‐cytolytic tumor‐associated antigen‐specific CD4+ T cell clone able to induce the DTH response in concert with lentinan reconstituted the antitumor effects in B6 nude mice when administered with lentinan. These results suggest that, in addition to the augmentation of immune effector cell activity against tumors, infiltration of these cells into the tumor burden initiated by the DTH responses at tumor sites may be involved in eradication of tumors by lentinan.

Từ khóa


Tài liệu tham khảo

10.1016/S0065-230X(08)60756-3

Fujimoto S., 1976, Regulation of the immune response to tumor antigens. I. Immunosuppressor cells in tumor‐bearing hosts, J. Immunol., 116, 791, 10.4049/jimmunol.116.3.791

10.1038/scientificamerican0577-62

10.1084/jem.154.4.1033

Hosakawa M., 1988, Improved therapeutic effects of interleukin 2 after the accumulation of lymphokine‐activated killed cells in tumor tissue of mice previously treated with cyclophosphamide, Cancer Immunol. Immunother., 26, 250

Lotze M. T., 1980, The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): implications for the adoptive immunotherapy of tumors, J. Immunol., 125, 1487, 10.4049/jimmunol.125.4.1487

Trial J., 1988, Cooperation between early acting delayed‐hypersensitivity T‐cell and cultured cells in tumor rejection, Cancer Res., 48, 5922

Hamuro J., Immune Modulation Agents and Their Mechanisms, 409

Suga T., 1984, Antitumor activity of lentinan in murine syngeneic and autochthonous hosts and its suppressive effects on 3‐methyl‐cholanthrene‐induced carcinogenesis, Cancer Res., 44, 5132

10.1002/ijc.2910080106

10.1016/0192-0561(90)90098-8

Masuko Y., 1982, Changes of antitumor immunity of hosts with murine mammary tumors regressed by lentinan: potentiation of antitumor delayed hypersensitivity reaction, Gann, 73, 790

Iwashiro M., 1993, Multiplicity of virus‐encoded helper T‐cell epitopes expressed on FBL‐3 tumor cells, J. Virol., 67, 4533, 10.1128/jvi.67.8.4533-4542.1993

10.1016/S0008-6215(00)83552-1

Dialynas D. P., 1983, Characterization of the murine T call surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to the human Leu3/T4 molecule, J. Immunol., 131, 2445, 10.4049/jimmunol.131.5.2445

10.1084/jem.161.2.345

Koo G. C., 1986, The NK1.1(—)mouse: a model to study differentiation of murine NK cells, J. Immunol., 137, 3742, 10.4049/jimmunol.137.12.3742

10.1084/jem.161.5.1122

10.1084/jem.157.5.1448

Shu S., 1987, Generation from tumor‐bearing mice of lymphocytes with in vivo therapeutic efficacy, J. Immunol., 139, 295, 10.4049/jimmunol.139.1.295

Fujiwara H., 1980, The augmentation of in vivo tumor‐specific T cell‐mediated immunity by amplifier T lymphocytes, J. Immunol., 124, 863, 10.4049/jimmunol.124.2.863

Fujiwara H., 1984, The role of tumor‐specific Lyt‐1+2− T cells in eradicating tumor cells in vivo. I. Lyt‐1+2− T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity, J Immunol., 133, 1671, 10.4049/jimmunol.133.3.1671

10.1111/j.1365-3083.1985.tb01897.x

10.1084/jem.162.3.943

Greenberg P. D., 1986, Therapy of murine leukemia with cyclophosphamide and immune Lyt2+ cells: cytolytic T cells can mediate eradication of disseminated leukemia, J. Immunol., 136, 1917, 10.4049/jimmunol.136.5.1917

10.1111/j.1349-7006.1989.tb01692.x

Yoshimura A., 1993, Rejection of an I‐A+ variant line of FBL‐3 leukemia by cytotoxic T lymphocytes with CD4+ and CD4− CD8− T cell receptor‐αβ phenotypes generated in CD8‐depleted C57BL/6 mice, J. Immunol., 150, 4900, 10.4049/jimmunol.150.11.4900

10.1084/jem.144.3.776

10.1016/0167-5699(87)90186-1

10.1084/jem.152.5.1358

Askenase P. W., 1982, Localization of leucocytes in site of delayed‐type hypersensitivity and in lymph nodes: dependence on vasoactive amines, Immunology, 47, 239

10.1016/0192-0561(84)90088-2

10.1016/0192-0561(91)90051-8

10.1007/BF01926482

Thông tin
Thông tin xuất bản

Wiley

Tập 85 Số 4

409-417

Thông tin tác giả